Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

2010 is a $0.5 million grant Anadys was awarded under the U.S. government's Qualifying Therapeutic Discovery Project program.  The remaining decrease was primarily attributable to a $0.5 million decrease in ANA598 development costs and a $0.4 million decrease in ANA773 development costs.General and administrative expenses were $1.7 million for the fourth quarter of 2010, compared to $1.6 million for the fourth quarter of 2009.  The general and administrative expenses were relatively consistent for the fourth quarter of 2010 when compared to the fourth quarter of 2009.

Anadys' net loss was $2.4 million for the fourth quarter of 2010, compared to a net loss of $4.3 million for the fourth quarter of 2009.  Included in the net loss for the fourth quarter of 2010 is a $2.0 million gain resulting from a decrease in the Company's common stock warrant liability from September 30, 2010 to December 31, 2010.  The liability is associated with warrants that were issued in connection with our "registered direct" offering in June 2009.  Basic and diluted net loss per common share was $0.04 in the fourth quarter of 2010, compared to $0.11 in the fourth quarter of 2009.  

For the twelve months ended December 31, 2010, Anadys reported a net loss of $16.3 million, compared to $27.3 million for the twelve months ended December 31, 2009.  Basic and diluted net loss per common share was $0.38 and $0.81 for the twelve months ended December 31, 2010 and 2009, respectively.

2010 Data Presentations

  • AASLD 2010, Oral Presentation – results through 12 weeks from a Phase IIa study of ANA598 were reported.  ANA598 added to SOC accelerated the rate of viral clearance, with comparable response at ANA598 doses of 200 mg bid and 400 mg bid.  ANA598 also showed an excellent resistance profile and safety profile through 12 weeks of dosing in the study, with reported adverse events being typical for patients
    '/>"/>

  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
    4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
    5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
    6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
    (Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
    (Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
    (Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
    Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
    ... September 1, 2010, ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
    ... Primary Endpoint in Second Phase III Trial in VMA, Confirms... -- LEUVEN, Belgium, September 1, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
    ... that a new market research report is available ... - Pipeline Assessment and Market Forecasts to 2017 ... Women,s Infertility - Pipeline Assessment and Market ... industry analysis specialist, has released its new report, ...
    Cached Biology Technology:EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 2EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 3EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 4EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 5EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 6EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 2Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 3Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 4Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 5Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 6Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 8Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 9Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 10Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 11Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 6
    (Date:7/9/2014)... ranges in which animals can be found, concern mounts ... an increased range for a host mean new territory ... a team of UC Santa Barbara scientists, including parasitologists ... in the Journal of Biogeography , Hechinger, Kuris ... may happen: Hosts may actually lose their parasites when ...
    (Date:7/9/2014)... Emerging fungal pathogens pose a greater threat ... population declines of amphibians, bats, corals, bees and ... Florida published in the prestigious journal Nature ... immunological resistance to a deadly chytrid fungus implicated ... resistance is important because it is the basis ...
    (Date:7/9/2014)... children with traumatic injuries have identified an immune ... develop a hospital-acquired infection. The study, led by ... in June in the journal Shock , ... lead to the clinical implementation of quick-turnaround immune ... immune system damage following critical illness or injury ...
    Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
    ... Global Information Inc is pleased to offer attendees their ... the world. Early Bird registration prices end as early ... to 15%. (Photo: http://photos.prnewswire.com/prnh/20120918/CG76491 ) ... | San Francisco, California CHI,s High-Content Analysis ...
    ... ARLINGTON, Va.Dr. John P. Holdren, White House Office of ... powerful roster of military and government leaders at the ... Conference and ASNE Expo, officials announced Sept. 18. ... S&T and co-chair of the President,s Council of Advisors ...
    ... is one of the most serious complications related to ... grown in Peru and Chile is a relative of ... The maize is rich in anthocyanins (also known as ... from the Department of Food and Nutrition and Department ...
    Cached Biology News:International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 3International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 4ONR lines up speakers and technologies for 2012 Naval Conference 2Purple corn compound may aid in developing future treatments for Type 2 diabetes, kidney disease 2
    ... cell with multi-casting chamber is used for handcasting ... format handcast (8.3 x 7.3 cm) or precast ... 3.4-4.4 L of buffer and includes an electrophoresis ... an external refrigerated circulator (not included), lid with ...
    ...
    ... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
    ...
    Biology Products: